Xencor (XNCR) Share-based Compensation (2013 - 2026)
Xencor (XNCR) posted quarterly Share-based Compensation of $9.6 million for Q1 2026, down 21.71% year-over-year from $12.2 million in Q1 2025, and down 6.13% quarter-over-quarter from $10.2 million in Q4 2025.
Analysis
Xencor (XNCR) Share-based Compensation (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Share-based Compensation for 14 consecutive years, with $9.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 21.71% year-over-year to $9.6 million; the TTM figure through Mar 2026 stood at $40.6 million (down 24.96% YoY), while the FY2025 annual figure was $43.2 million, down 18.87% from the prior year.
- Share-based Compensation eased to $9.6 million in Q1 2026 per XNCR's latest filing, from $10.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $51.3 million in Q4 2023 and bottomed at -$30.0 million in Q4 2022.
- Historically, Share-based Compensation has averaged $11.9 million across 5 years, with a median of $12.3 million in 2024.
- On a YoY basis, Share-based Compensation climbed as much as 1295.68% in 2022 and fell as far as 1082.08% in 2022.
- Xencor's Share-based Compensation stood at -$30.0 million in 2022, then soared by 270.9% to $51.3 million in 2023, then sank by 75.96% to $12.3 million in 2024, then declined by 17.41% to $10.2 million in 2025, then slipped by 6.13% to $9.6 million in 2026.
- Business Quant data shows XNCR's Share-based Compensation at $9.6 million in Q1 2026, $10.2 million in Q4 2025, and $10.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 9.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.19 Mn |
| Mar 31, 2026 | 9.56 Mn |
| Dec 31, 2025 | 10.19 Mn |
| Sep 30, 2025 | 10.09 Mn |
| Jun 30, 2025 | 10.74 Mn |
| Mar 31, 2025 | 12.21 Mn |
| Dec 31, 2024 | 12.33 Mn |
| Sep 30, 2024 | 12.34 Mn |
| Jun 30, 2024 | 17.19 Mn |
| Mar 31, 2024 | 11.42 Mn |
| Dec 31, 2023 | 14.70 Mn |
| Sep 30, 2023 | 12.90 Mn |
| Jun 30, 2023 | 13.56 Mn |
| Mar 31, 2023 | 12.60 Mn |
| Dec 31, 2022 | 12.75 Mn |
| Sep 30, 2022 | 14.97 Mn |
| Jun 30, 2022 | 15.06 Mn |
| Mar 31, 2022 | 15.32 Mn |
| Dec 31, 2021 | 10.39 Mn |
| Sep 30, 2021 | 13.24 Mn |